Researchers identified a novel gene that may predispose individuals to Cowden syndrome, an inherited condition that carries an especially high risk for various epithelial cancers and especially thyroid cancer.
The coexistence of mutations in telomerase reverse transcriptase (TERT) and BRAF genes dramatically increases the risk of thyroid cancer aggressiveness, tumor recurrence and thyroid cancer-specific deaths.
Researchers in Germany appear to have identified a gene-expression signature associated with metastasis in sporadic medullary thyroid cancer and prognostic molecular tumor markers of medullary thyroid cancer response to vandetanib therapy.
For patients who can tolerate aggressive multimodal therapy for anaplastic thyroid carcinoma, survival rates can exceed historical outcomes, according to a retrospective study of patients treated at the Mayo Clinic.
In this video, Steven I. Sherman, MD, discusses the final overall survival analysis of the EXAM study, a randomized, placebo-controlled phase III trial of cabozantinib in medullary thyroid carcinoma patients.
Josh Kremer, MD, vice president of clinical development at Eisai, Inc, discusses results of the phase III SELECT trial, which studied lenvatinib in radioiodine-refractory differentiated thyroid cancer.